Short Interest in Neuphoria Therapeutics Inc. (NASDAQ:NEUP) Increases By 327.4%

Neuphoria Therapeutics Inc. (NASDAQ:NEUP) saw a significant growth in short interest during the month of July. As of July 31st, there was short interest totaling 65,538 shares, a growth of 327.4% from the July 15th total of 15,334 shares. Based on an average trading volume of 638,720 shares, the days-to-cover ratio is currently 0.1 days. Approximately 1.2% of the company’s stock are sold short.

Institutional Investors Weigh In On Neuphoria Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the company. Millennium Management LLC acquired a new stake in Neuphoria Therapeutics in the third quarter valued at $216,000. Geode Capital Management LLC grew its stake in shares of Neuphoria Therapeutics by 33.3% during the 4th quarter. Geode Capital Management LLC now owns 17,303 shares of the company’s stock worth $67,000 after purchasing an additional 4,325 shares during the period. AdvisorShares Investments LLC increased its holdings in shares of Neuphoria Therapeutics by 129.1% in the 4th quarter. AdvisorShares Investments LLC now owns 134,194 shares of the company’s stock valued at $521,000 after purchasing an additional 75,631 shares in the last quarter. Commonwealth Equity Services LLC purchased a new position in shares of Neuphoria Therapeutics in the 4th quarter valued at about $43,000. Finally, Persistent Asset Partners Ltd lifted its stake in shares of Neuphoria Therapeutics by 173.1% in the fourth quarter. Persistent Asset Partners Ltd now owns 13,403 shares of the company’s stock valued at $52,000 after purchasing an additional 8,495 shares during the period. Institutional investors and hedge funds own 15.90% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently issued reports on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Neuphoria Therapeutics in a research report on Monday, June 1st. HC Wainwright lowered Neuphoria Therapeutics from a “buy” rating to a “neutral” rating in a research report on Friday, May 15th. Finally, Wall Street Zen upgraded Neuphoria Therapeutics to a “hold” rating in a research note on Saturday, July 25th. One equities research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Neuphoria Therapeutics currently has a consensus rating of “Hold” and an average price target of $21.00.

Neuphoria Therapeutics Trading Up 0.5%

Shares of NASDAQ NEUP traded up $0.02 during trading hours on Wednesday, reaching $3.83. The stock had a trading volume of 9,290 shares, compared to its average volume of 107,893. The firm has a market cap of $20.68 million, a price-to-earnings ratio of -0.35 and a beta of 0.75. Neuphoria Therapeutics has a fifty-two week low of $3.19 and a fifty-two week high of $21.40. The firm has a 50-day moving average of $3.97 and a 200-day moving average of $4.38.

Neuphoria Therapeutics (NASDAQ:NEUP) last announced its earnings results on Friday, May 15th. The company reported ($0.09) EPS for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.47. On average, equities analysts predict that Neuphoria Therapeutics will post -4.07 EPS for the current year.

Neuphoria Therapeutics Company Profile

Neuphoria Therapeutics, Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.